BiologicsSpineTop Stories

Royal Biologics Acquires FIBRINET

In its quest to add novel technologies to its line of autologous and live cellular solutions for orthopedic and spinal fusion. Hackensack, New Jersey-based Royal Biologics has announced the completed acquisition of FIBRINET, from Vertical Spine LLC.

FIBRINET, which uses a patient’s own autologous blood to create a platelet-rich fibrin matrix/membrane (PRFM), involves harvesting the patient’s autologous platelets through centrifugation and then combining them with a proprietary solution to solidify into a fibrin clot/membrane.

According to the company, “FIBRINET is the first commercialized system that utilizes a non-thrombin solution to create a reproducible platelet-rich fibrin matrix. The use of its proprietary solution to solidify a fibrin membrane provides the unique advantage of creating a biologic reservoir of growth factors and stem cells that can be held and used at the point of care for spinal fusion.”

“We are extremely excited to add FIBRINET to our growing portfolio of autologous and live cellular therapies,” says Salvatore Leo, Royal Biologics Chief Executive Officer. “FIBRINET’S technology now allows surgeons to harvest a patient’s autologous cells and create a unique platelet-rich fibrin membrane-scaffold to be used at the point of care in most spinal fusion procedures. When added to our current product portfolio of autologous and live cellular therapies, we feel that providing each patient an opportunity to harvest their own unique cells for treatment is a superior option in many surgical settings.”

Hospitals that have adopted the FIBRINET system include Hospital for Special Surgery, Mount Sinai, NY Presbyterian and Connecticut’s Orthopaedic Institute.

A European Spine Journal study, at a one-year follow-up, found that FIBRINET demonstrated over a 92.4% radiographic fusion, and a significant improvement recorded in Visual Analog Scores for both back and leg pain. Compared to baseline figures, the number of patients using opioid analgesics at 12 months decreased by 38%. While the majority (31/50) of patients that participated in the study were retired, 68% of the employed patients were able to return to work.1

Salvatore Leo told OSN, “We saw this technology, Platelet Rich Fibrin Matrix, as the perfect asset to add to our growing portfolio of Autologous and Live Cellular solutions. We have the ability to create a live cellular graft, point of care, at a fraction of the cost of other expensive non-live bone graft substitute options.”

Asked where they hope to ‘be’ one year from now with this system, Leo commented to OSN, “We hope to have expanded the Autologous Live Cellular portfolio to have FIBRINET as our flagship product line. FIBRINET is a leading biologic option for spinal fusion.” 

Royal Biologics has launched a new 3D animated movie that demonstrates the unique features of FIBRINET’s technology.

References:

1“Single‑center, consecutive series study of the use of a novel platelet‑rich fibrin matrix (PRFM) and beta‑tricalcium phosphate in posterolateral lumbar fusion,” European Spine Journal https://doi.org/10.1007/s00586-018-5832-5, July 16, 2018.

Print Friendly, PDF & Email
Tags

Elizabeth Hofheinz

Two time winner of the MORE award Ms. Hofheinz was the first writer employed by Orthopedics This Week. The MORE award is granted annually by the American Academy of Orthopaedic Surgeons to recognize excellence in journalism. Ms. Hofheinz is currently the Director of Communications for Ortho Spine Partners (OSP).

Related Articles

Back to top button
Close